1
|
Steyn C, Mishi R, Fillmore S, Verhoog MB, More J, Rohlwink UK, Melvill R, Butler J, Enslin JMN, Jacobs M, Sauka-Spengler T, Greco M, Quiñones S, Dulla CG, Raimondo JV, Figaji A, Hockman D. Cell type-specific gene expression dynamics during human brain maturation. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2024:2023.09.29.560114. [PMID: 37808657 PMCID: PMC10557738 DOI: 10.1101/2023.09.29.560114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/10/2023]
Abstract
The human brain undergoes protracted post-natal maturation, guided by dynamic changes in gene expression. Most studies exploring these processes have used bulk tissue analyses, which mask cell type-specific gene expression dynamics. Here, using single nucleus (sn)RNA-seq on temporal lobe tissue, including samples of African ancestry, we build a joint paediatric and adult atlas of 75 cell subtypes, which we verify with spatial transcriptomics. We explore the differences between paediatric and adult cell types, revealing the genes and pathways that change during brain maturation. Our results highlight excitatory neuron subtypes, including the LTK and FREM subtypes, that show elevated expression of genes associated with cognition and synaptic plasticity in paediatric tissue. The new resources we present here improve our understanding of the brain during its development and contribute to global efforts to build an inclusive brain cell map.
Collapse
Affiliation(s)
- Christina Steyn
- Division of Cell Biology, Department of Human Biology, University of Cape Town, Cape Town, South Africa
- Neuroscience Institute, University of Cape Town, Cape Town, South Africa
| | - Ruvimbo Mishi
- Division of Cell Biology, Department of Human Biology, University of Cape Town, Cape Town, South Africa
- Neuroscience Institute, University of Cape Town, Cape Town, South Africa
| | - Stephanie Fillmore
- Division of Cell Biology, Department of Human Biology, University of Cape Town, Cape Town, South Africa
- Neuroscience Institute, University of Cape Town, Cape Town, South Africa
| | - Matthijs B Verhoog
- Division of Cell Biology, Department of Human Biology, University of Cape Town, Cape Town, South Africa
- Neuroscience Institute, University of Cape Town, Cape Town, South Africa
| | - Jessica More
- Division of Cell Biology, Department of Human Biology, University of Cape Town, Cape Town, South Africa
- Neuroscience Institute, University of Cape Town, Cape Town, South Africa
| | - Ursula K Rohlwink
- Neuroscience Institute, University of Cape Town, Cape Town, South Africa
- Division of Neurosurgery, Department of Surgery, University of Cape Town, Cape Town, South Africa
| | - Roger Melvill
- Division of Neurosurgery, Department of Surgery, University of Cape Town, Cape Town, South Africa
| | - James Butler
- Neuroscience Institute, University of Cape Town, Cape Town, South Africa
- Division of Neurology, Department of Medicine, University of Cape Town, Cape Town, South Africa
| | - Johannes M N Enslin
- Neuroscience Institute, University of Cape Town, Cape Town, South Africa
- Division of Neurosurgery, Department of Surgery, University of Cape Town, Cape Town, South Africa
| | - Muazzam Jacobs
- Neuroscience Institute, University of Cape Town, Cape Town, South Africa
- Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
- Division of Immunology, Department of Pathology University of Cape Town
- National Health Laboratory Service, South Africa
| | - Tatjana Sauka-Spengler
- Radcliffe Department of Medicine, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
- Stowers Institute for Medical Research, Kansas City, MO, USA
| | - Maria Greco
- Single Cell Facility, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - Sadi Quiñones
- Department of Neuroscience, Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA
- Graduate School of Biomedical Science, Tufts University School of Medicine, Boston, MA, USA
| | - Chris G Dulla
- Department of Neuroscience, Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA
| | - Joseph V Raimondo
- Division of Cell Biology, Department of Human Biology, University of Cape Town, Cape Town, South Africa
- Neuroscience Institute, University of Cape Town, Cape Town, South Africa
- Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
| | - Anthony Figaji
- Neuroscience Institute, University of Cape Town, Cape Town, South Africa
- Division of Neurosurgery, Department of Surgery, University of Cape Town, Cape Town, South Africa
| | - Dorit Hockman
- Division of Cell Biology, Department of Human Biology, University of Cape Town, Cape Town, South Africa
- Neuroscience Institute, University of Cape Town, Cape Town, South Africa
| |
Collapse
|
2
|
Cheng C, Zhu G, Wang K, Bu C, Li S, Qiu Y, Lu J, Ji X, Hao W, Wang J, Zhu C, Yang Y, Gu Y, Qian X, Yu C, Gao X. Deletion of Luzp2 Does Not Cause Hearing Loss in Mice. Neurosci Bull 2024:10.1007/s12264-024-01202-5. [PMID: 38589712 DOI: 10.1007/s12264-024-01202-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2023] [Accepted: 11/19/2023] [Indexed: 04/10/2024] Open
Abstract
Deafness is the prevailing sensory impairment among humans, impacting every aspect of one's existence. Half of congenital deafness cases are attributed to genetic factors. Studies have shown that Luzp2 is expressed in hair cells (HCs) and supporting cells of the inner ear, but its specific role in hearing remains unclear. To determine the importance of Luzp2 in auditory function, we generated mice deficient in Luzp2. Our results revealed that Luzp2 has predominant expression within the HCs and pillar cells. However, the loss of Luzp2 did not result in any changes in auditory threshold. HCs or synapse number and HC stereocilia morphology in Luzp2 knockout mice did not show any notable distinctions. This was the first study of the role of Luzp2 in hearing in mice, and our results provide important guidance for the screening of deafness genes.
Collapse
Affiliation(s)
- Cheng Cheng
- Department of Otolaryngology-Head and Neck Surgery, Drum Tower Hospital, Affiliated Hospital of the Medical School, Jiangsu Provincial Key Medical Discipline (Laboratory), Nanjing University, Nanjing, 210008, China
- Research Institute of Otolaryngology, Nanjing, 210008, China
| | - Guangjie Zhu
- Department of Otolaryngology-Head and Neck Surgery, Drum Tower Hospital, Affiliated Hospital of the Medical School, Jiangsu Provincial Key Medical Discipline (Laboratory), Nanjing University, Nanjing, 210008, China
- Research Institute of Otolaryngology, Nanjing, 210008, China
| | - Kaijian Wang
- Department of Otorhinolaryngology, Qidong People's Hospital, Qidong Liver Cancer Institute, Affiliated Qidong Hospital of Nantong University, Nantong, 226200, China
| | - Chuan Bu
- The First Affiliated Hospital of Kangda College of Nanjing Medical University, The First People's Hospital of Lianyungang, Lianyungang, 222000, China
| | - Siyu Li
- Department of Otolaryngology-Head and Neck Surgery, Drum Tower Hospital, Affiliated Hospital of the Medical School, Jiangsu Provincial Key Medical Discipline (Laboratory), Nanjing University, Nanjing, 210008, China
| | - Yue Qiu
- Department of Otolaryngology-Head and Neck Surgery, Drum Tower Hospital, Affiliated Hospital of the Medical School, Jiangsu Provincial Key Medical Discipline (Laboratory), Nanjing University, Nanjing, 210008, China
| | - Jie Lu
- Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, 225001, China
| | - Xinya Ji
- Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, 225001, China
| | - Wenli Hao
- Department of Otolaryngology-Head and Neck Surgery, Drum Tower Hospital, Affiliated Hospital of the Medical School, Jiangsu Provincial Key Medical Discipline (Laboratory), Nanjing University, Nanjing, 210008, China
| | - Junguo Wang
- Department of Otolaryngology-Head and Neck Surgery, Drum Tower Hospital, Affiliated Hospital of the Medical School, Jiangsu Provincial Key Medical Discipline (Laboratory), Nanjing University, Nanjing, 210008, China
- Research Institute of Otolaryngology, Nanjing, 210008, China
| | - Chengwen Zhu
- Department of Otolaryngology-Head and Neck Surgery, Drum Tower Hospital, Affiliated Hospital of the Medical School, Jiangsu Provincial Key Medical Discipline (Laboratory), Nanjing University, Nanjing, 210008, China
- Research Institute of Otolaryngology, Nanjing, 210008, China
| | - Ye Yang
- Department of Otolaryngology-Head and Neck Surgery, Drum Tower Hospital, Affiliated Hospital of the Medical School, Jiangsu Provincial Key Medical Discipline (Laboratory), Nanjing University, Nanjing, 210008, China
- Research Institute of Otolaryngology, Nanjing, 210008, China
| | - Yajun Gu
- Department of Otolaryngology-Head and Neck Surgery, Drum Tower Hospital, Affiliated Hospital of the Medical School, Jiangsu Provincial Key Medical Discipline (Laboratory), Nanjing University, Nanjing, 210008, China
| | - Xiaoyun Qian
- Department of Otolaryngology-Head and Neck Surgery, Drum Tower Hospital, Affiliated Hospital of the Medical School, Jiangsu Provincial Key Medical Discipline (Laboratory), Nanjing University, Nanjing, 210008, China
- Research Institute of Otolaryngology, Nanjing, 210008, China
| | - Chenjie Yu
- Department of Otolaryngology-Head and Neck Surgery, Drum Tower Hospital, Affiliated Hospital of the Medical School, Jiangsu Provincial Key Medical Discipline (Laboratory), Nanjing University, Nanjing, 210008, China.
- Research Institute of Otolaryngology, Nanjing, 210008, China.
| | - Xia Gao
- Department of Otolaryngology-Head and Neck Surgery, Drum Tower Hospital, Affiliated Hospital of the Medical School, Jiangsu Provincial Key Medical Discipline (Laboratory), Nanjing University, Nanjing, 210008, China.
- Research Institute of Otolaryngology, Nanjing, 210008, China.
| |
Collapse
|
3
|
An Alzheimer’s Disease Patient-Derived Olfactory Stem Cell Model Identifies Gene Expression Changes Associated with Cognition. Cells 2022; 11:cells11203258. [PMID: 36291125 PMCID: PMC9601087 DOI: 10.3390/cells11203258] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Revised: 10/07/2022] [Accepted: 10/11/2022] [Indexed: 11/25/2022] Open
Abstract
An early symptom of Alzheimer’s disease (AD) is an impaired sense of smell, for which the molecular basis remains elusive. Here, we generated human olfactory neurosphere-derived (ONS) cells from people with AD and mild cognitive impairment (MCI), and performed global RNA sequencing to determine gene expression changes. ONS cells expressed markers of neuroglial differentiation, providing a unique cellular model to explore changes of early AD-associated pathways. Our transcriptomics data from ONS cells revealed differentially expressed genes (DEGs) associated with cognitive processes in AD cells compared to MCI, or matched healthy controls (HC). A-Kinase Anchoring Protein 6 (AKAP6) was the most significantly altered gene in AD compared to both MCI and HC, and has been linked to cognitive function. The greatest change in gene expression of all DEGs occurred between AD and MCI. Gene pathway analysis revealed defects in multiple cellular processes with aging, intellectual deficiency and alternative splicing being the most significantly dysregulated in AD ONS cells. Our results demonstrate that ONS cells can provide a cellular model for AD that recapitulates disease-associated differences. We have revealed potential novel genes, including AKAP6 that may have a role in AD, particularly MCI to AD transition, and should be further examined.
Collapse
|
4
|
Ding H, Shi L, Chen Z, Lu Y, Tian Z, Xiao H, Deng X, Chen P, Zhang Y. Construction and evaluation of a prognostic risk model of tumor metastasis-related genes in patients with non-small cell lung cancer. BMC Med Genomics 2022; 15:187. [PMID: 36056349 PMCID: PMC9440521 DOI: 10.1186/s12920-022-01341-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2022] [Accepted: 08/22/2022] [Indexed: 11/14/2022] Open
Abstract
Background Lung cancer is a high-incidence cancer, and it is also the most common cause of cancer death worldwide. 80–85% of lung cancer cases can be classified as non-small cell lung cancer (NSCLC). Methods NSCLC transcriptome data and clinical information were downloaded from the TCGA database and GEO database. Firstly, we analyzed and identified the differentially expressed genes (DEGs) between non-metastasis group and metastasis group of NSCLC in the TCGA database, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) were consulted to explore the functions of the DEGs. Thereafter, univariate Cox regression and LASSO Cox regression algorithms were applied to identify prognostic metastasis-related signature, followed by the construction of the risk score model and nomogram for predicting the survival of NSCLC patients. GSEA analyzed that differentially expressed gene-related signaling pathways in the high-risk group and the low-risk group. The survival of NSCLC patients was analyzed by the Kaplan–Meier method. ROC curve was plotted to evaluate the accuracy of the model. Finally, the GEO database was further applied to verify the metastasis‑related prognostic signature. Results In total, 2058 DEGs were identified. GO functions and KEGG pathways analysis results showed that the DEGs mainly concentrated in epidermis development, skin development, and the pathway of Neuro active ligand -receptor interaction in cancer. A six-gene metastasis-related risk signature including C1QL2, FLNC, LUZP2, PRSS3, SPIC, and GRAMD1B was constructed to predict the overall survival of NSCLC patients. The reliability of the gene signature was verified in GSE13213. The NSCLC patients were grouped into low-risk and high-risk groups based on the median value of risk scores. And low-risk patients had lower risk scores and longer survival time. Univariate and multivariate Cox regression verified that this signature was an independent risk factor for NSCLC. Conclusion Our study identified 6 metastasis biomarkers in the NSCLC. The biomarkers may contribute to individual risk estimation, survival prognosis.
Collapse
Affiliation(s)
- Huan Ding
- Changchun University of Traditional Chinese Medicine, No. 1035 Boshuo Road, Jingyue National High-Tech Industrial Development Zone, Changchun, 130117, China
| | - Li Shi
- Affiliated Hospital of Changchun University of Chinese Medicine, No. 1478, Gongnongda Road, Changchun, 130021, China
| | - Zhuo Chen
- Jilin Provincial Cancer Hospital, No. 1066, Jinhu Road, Changchun, 130021, China
| | - Yi Lu
- Jilin Provincial Cancer Hospital, No. 1066, Jinhu Road, Changchun, 130021, China
| | - Zhiyu Tian
- Changchun University of Traditional Chinese Medicine, No. 1035 Boshuo Road, Jingyue National High-Tech Industrial Development Zone, Changchun, 130117, China
| | - Hongyu Xiao
- Jilin Provincial Cancer Hospital, No. 1066, Jinhu Road, Changchun, 130021, China
| | - Xiaojing Deng
- Changchun University of Traditional Chinese Medicine, No. 1035 Boshuo Road, Jingyue National High-Tech Industrial Development Zone, Changchun, 130117, China
| | - Peiyi Chen
- Changchun University of Traditional Chinese Medicine, No. 1035 Boshuo Road, Jingyue National High-Tech Industrial Development Zone, Changchun, 130117, China
| | - Yue Zhang
- Jilin Provincial Cancer Hospital, No. 1066, Jinhu Road, Changchun, 130021, China.
| |
Collapse
|
5
|
Vogrinc D, Goričar K, Dolžan V. Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review. Front Aging Neurosci 2021; 13:646901. [PMID: 33815092 PMCID: PMC8012500 DOI: 10.3389/fnagi.2021.646901] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2020] [Accepted: 02/16/2021] [Indexed: 12/14/2022] Open
Abstract
Alzheimer's disease (AD) is a complex neurodegenerative disease, affecting a significant part of the population. The majority of AD cases occur in the elderly with a typical age of onset of the disease above 65 years. AD presents a major burden for the healthcare system and since population is rapidly aging, the burden of the disease will increase in the future. However, no effective drug treatment for a full-blown disease has been developed to date. The genetic background of AD is extensively studied; numerous genome-wide association studies (GWAS) identified significant genes associated with increased risk of AD development. This review summarizes more than 100 risk loci. Many of them may serve as biomarkers of AD progression, even in the preclinical stage of the disease. Furthermore, we used GWAS data to identify key pathways of AD pathogenesis: cellular processes, metabolic processes, biological regulation, localization, transport, regulation of cellular processes, and neurological system processes. Gene clustering into molecular pathways can provide background for identification of novel molecular targets and may support the development of tailored and personalized treatment of AD.
Collapse
Affiliation(s)
| | | | - Vita Dolžan
- Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
| |
Collapse
|
6
|
Downregulation of LUZP2 Is Correlated with Poor Prognosis of Low-Grade Glioma. BIOMED RESEARCH INTERNATIONAL 2020; 2020:9716720. [PMID: 32695826 PMCID: PMC7368956 DOI: 10.1155/2020/9716720] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/25/2019] [Revised: 05/27/2020] [Accepted: 06/11/2020] [Indexed: 12/26/2022]
Abstract
Background LUZP2 is a protein limitedly expressed in the brain and spinal cord, while there are few studies on it in brain tumors. Low-grade glioma (LGG) is one of the most common brain tumors. However, the biological behavior of LGG is not very clear at present. This study was aimed at exploring the role of LUZP2 in LGG. Methods By data mining in The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA), the expression, clinical characteristics, and potential regulatory mechanism of LUZP2 in LGG were assessed. The regulatory miRNAs of LUZP2 were predicted using miRDB, TargetScan, and miRTarBase. Meanwhile, the potential biological function of coexpressed genes was investigated by GO and KEGG analyses. Results LUZP2 expression was downregulated with the increase of tumor grade (p < 0.05). Low LUZP2 expression independently predicted poor OS in LGG in TCGA cohort and the CGGA part B and part C cohorts (all p < 0.001). Additionally, LUZP2 was targeted by miR-142-5p according to 2 prediction databases and 1 validated database, which was negatively related to LUZP2 mRNA expression (p < 0.001). Kaplan-Meier analyses demonstrated that low miR-142-5p expression was significantly associated with poor OS (p < 0.001). Furthermore, coexpression genes of LUZP2 were significantly involved in nervous system development and metabolic pathways. Conclusions LUZP2 may be crucial for nervous system extracellular matrix development and serve as an important clinical biomarker for LGG patients. miR-142-5p upregulation could be the upstream regulator that contributed to LUZP2 downregulation.
Collapse
|
7
|
Fedorenko OY, Golimbet VE, Ivanova SА, Levchenko А, Gainetdinov RR, Semke AV, Simutkin GG, Gareeva АE, Glotov АS, Gryaznova A, Iourov IY, Krupitsky EM, Lebedev IN, Mazo GE, Kaleda VG, Abramova LI, Oleichik IV, Nasykhova YA, Nasyrova RF, Nikolishin AE, Kasyanov ED, Rukavishnikov GV, Timerbulatov IF, Brodyansky VM, Vorsanova SG, Yurov YB, Zhilyaeva TV, Sergeeva AV, Blokhina EA, Zvartau EE, Blagonravova AS, Aftanas LI, Bokhan NА, Kekelidze ZI, Klimenko TV, Anokhina IP, Khusnutdinova EK, Klyushnik TP, Neznanov NG, Stepanov VA, Schulze TG, Kibitov АО. Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium. Mol Psychiatry 2019; 24:1099-1111. [PMID: 30664668 PMCID: PMC6756082 DOI: 10.1038/s41380-019-0354-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2018] [Revised: 12/27/2018] [Accepted: 12/31/2018] [Indexed: 12/18/2022]
Abstract
We provide an overview of the recent achievements in psychiatric genetics research in the Russian Federation and present genotype-phenotype, population, epigenetic, cytogenetic, functional, ENIGMA, and pharmacogenetic studies, with an emphasis on genome-wide association studies. The genetic backgrounds of mental illnesses in the polyethnic and multicultural population of the Russian Federation are still understudied. Furthermore, genetic, genomic, and pharmacogenetic data from the Russian Federation are not adequately represented in the international scientific literature, are currently not available for meta-analyses and have never been compared with data from other populations. Most of these problems cannot be solved by individual centers working in isolation but warrant a truly collaborative effort that brings together all the major psychiatric genetic research centers in the Russian Federation in a national consortium. For this reason, we have established the Russian National Consortium for Psychiatric Genetics (RNCPG) with the aim to strengthen the power and rigor of psychiatric genetics research in the Russian Federation and enhance the international compatibility of this research.The consortium is set up as an open organization that will facilitate collaborations on complex biomedical research projects in human mental health in the Russian Federation and abroad. These projects will include genotyping, sequencing, transcriptome and epigenome analysis, metabolomics, and a wide array of other state-of-the-art analyses. Here, we discuss the challenges we face and the approaches we will take to unlock the huge potential that the Russian Federation holds for the worldwide psychiatric genetics community.
Collapse
Affiliation(s)
- Olga Yu Fedorenko
- Mental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation.
- National Research Tomsk Polytechnic University, Tomsk, Russian Federation.
| | | | - Svetlana А Ivanova
- Mental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation
- National Research Tomsk Polytechnic University, Tomsk, Russian Federation
| | - Аnastasia Levchenko
- Institute of Translational Biomedicine, Saint Petersburg State University, Saint Petersburg, Russian Federation
| | - Raul R Gainetdinov
- Institute of Translational Biomedicine, Saint Petersburg State University, Saint Petersburg, Russian Federation
| | - Arkady V Semke
- Mental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation
| | - German G Simutkin
- Mental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation
| | - Аnna E Gareeva
- Institute of Biochemistry and Genetics, Ufa Federal Research Center, Russian Academy of Sciences, Ufa, Russian Federation
- Federal State Educational Institution of Highest Education Bashkir State Medical University of Public Health Ministry of Russian Federation, Ufa, Russian Federation
| | - Аndrey S Glotov
- Laboratory of Biobanking and Genomic Medicine of Institute of Translational Biomedicine, Saint Petersburg State University, Saint Petersburg, Russian Federation
| | - Anna Gryaznova
- Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU, Munich, Germany
| | - Ivan Y Iourov
- Mental Health Research Center, Moscow, Russian Federation
| | - Evgeny M Krupitsky
- V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russian Federation
| | - Igor N Lebedev
- Research Institute of Medical Genetics, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation
| | - Galina E Mazo
- V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russian Federation
| | | | | | | | - Yulia A Nasykhova
- Laboratory of Biobanking and Genomic Medicine of Institute of Translational Biomedicine, Saint Petersburg State University, Saint Petersburg, Russian Federation
| | - Regina F Nasyrova
- V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russian Federation
| | - Anton E Nikolishin
- Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation
| | - Evgeny D Kasyanov
- V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russian Federation
| | - Grigory V Rukavishnikov
- V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russian Federation
| | - Ilgiz F Timerbulatov
- Federal State Educational Institution of Highest Education Bashkir State Medical University of Public Health Ministry of Russian Federation, Ufa, Russian Federation
| | - Vadim M Brodyansky
- Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation
| | - Svetlana G Vorsanova
- Veltischev Research and Clinical Institute for Pediatrics, the Pirogov Russian National Research Medical University, Moscow, Russian Federation
| | - Yury B Yurov
- Mental Health Research Center, Moscow, Russian Federation
| | - Tatyana V Zhilyaeva
- Privolzhskiy Research Medical University, Nizhny Novgorod, Russian Federation
| | | | - Elena A Blokhina
- First Saint Petersburg Pavlov State Medical University, Saint Petersburg, Russian Federation
| | - Edwin E Zvartau
- First Saint Petersburg Pavlov State Medical University, Saint Petersburg, Russian Federation
| | - Anna S Blagonravova
- Privolzhskiy Research Medical University, Nizhny Novgorod, Russian Federation
| | - Lyubomir I Aftanas
- Federal State Scientific Budgetary Institution "Scientific Research Institute of Physiology and Basic Medicine,", Novosibirsk, Russian Federation
| | - Nikolay А Bokhan
- Mental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation
- National Research Tomsk State University, Tomsk, Russian Federation
| | - Zurab I Kekelidze
- Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation
| | - Tatyana V Klimenko
- Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation
| | - Irina P Anokhina
- Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation
| | - Elza K Khusnutdinova
- Institute of Biochemistry and Genetics, Ufa Federal Research Center, Russian Academy of Sciences, Ufa, Russian Federation
- Federal State Educational Institution of Highest Education Bashkir State Medical University of Public Health Ministry of Russian Federation, Ufa, Russian Federation
| | | | - Nikolay G Neznanov
- V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russian Federation
| | - Vadim A Stepanov
- Research Institute of Medical Genetics, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation
- National Research Tomsk State University, Tomsk, Russian Federation
| | - Thomas G Schulze
- Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU, Munich, Germany
| | - Аleksandr О Kibitov
- Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation
| |
Collapse
|